companies innovating in obesity treatment glp-1 drugs 2025 Potential Emerging Therapies the Space Pharma Giants Bet on Next-Generation

[DOI] [PMC free article] [PubMed] [Google Scholar] 29.Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA

The acute side effects that EMS may be called for are generally gastrointestinal in nature

Akkermansia is not a replacement for GLP-1 medications, but it may help support the gut conditions tied to natural metabolic signaling, including mucosal integrity, SCFA production, inflammatory balance, and microbiome resilience

2021;46 doi: 10.1016/j.molmet.2020.101102

35 The recent phase 3 Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE) trial showed that semaglutide 2.4 mg once weekly improved liver histology in patients with metabolic dysfunction-associated steatohepatitis with moderate or advanced liver fibrosis

Insulin, in turn, helps lower blood glucose levels